Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day).

Trial Profile

Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day).

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2012 Planned number of patients changed from 370 to 500 as reported by European Clinical Trials Database record.
    • 12 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top